VUDALIMAB

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Investigational

Approval Year

Substance Class	Protein Created by `admin` on `Tue Apr 01 23:58:22 GMT 2025` Edited by `admin` on `Tue Apr 01 23:58:22 GMT 2025`
Protein Type	BISPECIFIC ANTIBODY
Protein Sub Type	IGG1
Sequence Origin	HUMANIZED
Sequence Type	COMPLETE
Record UNII	4I9I5X3Z6N
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VUDALIMAB

Official Name

English

XMAB-20717

Preferred Name

English

IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)) AND ANTI-(HOMO SAPIENSPDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), MONOCLONAL ANTIBODY, BISPECIFIC

Common Name

English

Vudalimab [WHO-DD]

Common Name

English

PD-1 X CTLA-4 DUAL CHECKPOINT INHIBITOR XMAB20717

Common Name

English

IMMUNOGLOBULIN, ANTI-(HUMAN CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB20717 SINGLE-CHAIN VARIABLE FRAGMENT VL-LINKER-VH) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN C-REGION C-TERMINAL FRAGMENT), (260

Common Name

English

ANTI-PD-1/ANTI-CTLA-4 XMAB20717

Common Name

English

XMAB20717

Code

English

VUDALIMAB [USAN]

Common Name

English

vudalimab [INN]

Common Name

English

ANTI-PD1/CTLA4 BISPECIFIC ANTIBODY XMAB20717

Common Name

English

Code System Code Type Description

NCI_THESAURUS

C150463

Created by admin on Tue Apr 01 23:58:22 GMT 2025 , Edited by admin on Tue Apr 01 23:58:22 GMT 2025

PRIMARY

SMS_ID

300000028760

Created by admin on Tue Apr 01 23:58:22 GMT 2025 , Edited by admin on Tue Apr 01 23:58:22 GMT 2025

PRIMARY

FDA UNII

4I9I5X3Z6N

Created by admin on Tue Apr 01 23:58:22 GMT 2025 , Edited by admin on Tue Apr 01 23:58:22 GMT 2025

PRIMARY

CAS

2329669-72-7

Created by admin on Tue Apr 01 23:58:22 GMT 2025 , Edited by admin on Tue Apr 01 23:58:22 GMT 2025

PRIMARY

CAS

2303884-42-4

Created by admin on Tue Apr 01 23:58:22 GMT 2025 , Edited by admin on Tue Apr 01 23:58:22 GMT 2025

NO STRUCTURE GIVEN

USAN

JK-26

Created by admin on Tue Apr 01 23:58:22 GMT 2025 , Edited by admin on Tue Apr 01 23:58:22 GMT 2025

PRIMARY

INN

11464

Created by admin on Tue Apr 01 23:58:22 GMT 2025 , Edited by admin on Tue Apr 01 23:58:22 GMT 2025

PRIMARY

From	To
1_22	1_96
1_145	1_201
1_221	3_215
1_227	2_260
1_230	2_263
1_261	1_321
1_367	1_425
2_23	2_88
2_149	2_225
2_294	2_354
2_400	2_458
3_23	3_89
3_135	3_195

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_297
N	2_330

Related Record Type Details


					938DNF64FO

PROGRAMMED CELL DEATH PROTEIN 1

TARGET -> INHIBITOR

Amount:


					KYU4T5WAI2

CYTOTOXIC T-LYMPHOCYTE PROTEIN 4

TARGET -> INHIBITOR

Amount:

Related Record Type Details


					4I9I5X3Z6N

VUDALIMAB

ACTIVE MOIETY

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO ACID REMOVAL	[1_447] [2_480]	C-TERMINUS		Amount:	LYSINE	K3Z4F929H6

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL
Molecular Formula	CHEMICAL